A post-discharge disease management program for patients with COPD positively impacts 90-day readmission rates.
1-Minute Consult: What Is the Role of Roflumilast in COPD?
Roflumilast’s benefit-to-harm ratio suggests that it only provides net benefit in patients at high risk of severe exacerbations.
Treating COPD Patients with a History of Frequent Exacerbations
Exacerbations of COPD are linked to poor clinical outcomes and high costs. We discuss the multiple pharmacotherapeutic options and how they may be used to prevent exacerbations.